Clinical Trial

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Study acronym: ORIGIN EXTEND
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-11-03; most recent amendment 2026-06-17.
Status change: Recruiting → Enrolling by Invitation 2025-04-04
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06674577
Lead Sponsor Vera Therapeutics, Inc.
Conditions IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
Enrollment 750 participants
Start Date 2024-12-01
Primary Completion 2031-05-21 (estimated)
Study Completion 2031-05-21 (estimated)
Updated on ClinicalTrials.gov 2026-06-22